[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-364103-105":59,"doc-detail-364103-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","genomic-profiling-of-epidermal-growth-factor-receptor-mutationpositive-nonsmall-cell-lung-cancer-after-progression-on-first-line-osimertinib-phase-ii-orchard-study","Genomic Profiling of Epidermal Growth Factor Receptor Mutation–Positive Non–Small Cell Lung Cancer after Progression on First-line Osimertinib - Phase II ORCHARD Study","","Genomic Profiling of Epidermal Growth Factor Receptor mutation–positive non–small cell lung cancer examines tumor molecular profiles in patients who progressed after first-line osimertinib. The ORCHARD phase II biomarker-directed study used next-generation sequencing of tumor biopsy and plasma samples to evaluate resistance mechanisms and assess agreement between tissue and plasma results. Results describe comprehensive tissue (n=400) and plasma (n=191) datasets, frequent mutually exclusive TP53 and MDM2/4 alterations, high resistance-alteration detection, and PI3K pathway and histologic transformation signals.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/genomic-profiling-of-epidermal-growth-factor-receptor-mutationpositive-nonsmall-cell-lung-cancer-after-progression-on-first-line-osimertinib-phase-ii-orchard-study/364103/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/genomic-profiling-of-epidermal-growth-factor-receptor-mutationpositive-nonsmall-cell-lung-cancer-after-progression-on-first-line-osimertinib-phase-ii-orchard-study/364103.png","ImageObject",300,407,{"name":92,"@type":93},"anakgang17","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-19","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",15,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the purpose of the ORCHARD phase II study?","Question",{"text":113,"@type":114},"To understand tumor molecular profiles after progression on first-line osimertinib and to help inform optimal second-line treatment by identifying resistance mechanisms through tissue and plasma NGS.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How did the study determine patient groups and resistance mechanisms?",{"text":118,"@type":114},"Patients with EGFRm NSCLC who progressed on osimertinib received treatment based on their tumor molecular profile. The profile was determined by next-generation sequencing of tumor biopsy, and results included prespecified exploratory analyses using baseline tumor tissue and plasma samples.",{"name":120,"@type":111,"acceptedAnswer":121},"What were the key genomic findings related to resistance?",{"text":122,"@type":114},"Resistance alterations were detected in 87% of samples when combining tissue and plasma genomics, with multiple resistance alterations in 46%. TP53 and MDM2/4 alterations were mutually exclusive and occurred in 86% of tumors, and PI3K pathway, SOX2, and MYC alterations were frequently observed in histologically transformed tumors.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},364103,1790409192,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},962090883568,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Genomic Profiling of Epidermal Growth Factor Receptor Mutation–Positive Non–Small Cell Lung Cancer after Progression on First-line Osimertinib:  \nPhase II ORCHARD Study  \nHelena A. Yu1, Kwan Ho Tang2, Aleksandra Markovets3, Ryan Hartmaier2, Paul E. Smith4, Byoung Chul Cho5, Adrianus Johannes De Langen6, Sarah B. Goldberg7, Jonathan W. Goldman8, Xiuning Le9, Eiji Iwama10, Jan Cosaert11, Jonathan W. Riess12, and Zofia Piotrowska13  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Purpose: Osimertinib is the standard of care for first-line treatment for epidermal growth factor receptor–mutated (EGFRm) non–small cell lung cancer (NSCLC) . Understanding the tumor molecular profile of patients following progression onosimertinib could help inform optimal second-line treatment.\u003Cbr>Patients and Methods: ORCHARD (NCT03944772), a phase II biomarker-directed study, enrolled patients with EGFRm NSCLC who progressed on first-line osimertinib to receive treatment based on their tumor molecular profile after progression. The study comprised three groups into which patients were allocated based on the molecular profile of their tumor, determined via nextgeneration sequencing (NGS) of a tumor biopsy. We report results from a prespecified, exploratory analysis of baseline tumor tissue and plasma samples to evaluate mechanisms of resistance to firstline osimertinib identified by tissue and plasma NGS. Agreement between tissue and plasma NGS data was also assessed.\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Results: This study provided a comprehensive dataset exploring tissue (n ¼ 400) and plasma (n ¼ 191) genomics, enabling characterization of the histogenomic landscape after firstline osimertinib treatment. TP53 and MDM2/4 alterations were mutually exclusive and occurred in 86% of tumors. When combining tissue and plasma genomics, resistance alterations were detected in 87% of samples, with multiple resistance alterations in 46% . Alterations in the PI3K pathway, SOX2, and MYC were frequently detected in histologically transformed tumors. Additionally, differential patterns of co-occurring EGFR mutations in tumors with L858R versus exon 19 deletion were observed.\u003Cbr>Conclusions: This comprehensive analysis highlights potential heterogeneous resistance to first-line osimertinib treatment, providing a rationale for combining treatments with broad activity to improve patient outcomes.\u003Cbr>See related commentary by Gupta et al., p. 3718 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\n1Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York. 2Translational Medicine, Oncology R&D, AstraZeneca, Boston, Massachusetts. 3Oncology Data Science and AI, Oncology R&D, AstraZeneca, Boston, Massachusetts. 4On behalf of Early Oncology, Oncology R&D, AstraZeneca, Cambridge, United Kingdom. 5Division of Medical Oncology, Yonsei Cancer Center, Yonsei","cbCain70QyMYtfXs","https://ap.wps.com/l/cbCain70QyMYtfXs","pdf",1731967,11,"English","# Purpose\n# Patients and Methods\n## ORCHARD study design and biomarker-directed grouping\n## Tissue and plasma NGS agreement\n# Results\n# Conclusions\n# Introduction","[{\"question\":\"What was the purpose of the ORCHARD phase II study?\",\"answer\":\"To understand tumor molecular profiles after progression on first-line osimertinib and to help inform optimal second-line treatment by identifying resistance mechanisms through tissue and plasma NGS.\"},{\"question\":\"How did the study determine patient groups and resistance mechanisms?\",\"answer\":\"Patients with EGFRm NSCLC who progressed on osimertinib received treatment based on their tumor molecular profile. The profile was determined by next-generation sequencing of tumor biopsy, and results included prespecified exploratory analyses using baseline tumor tissue and plasma samples.\"},{\"question\":\"What were the key genomic findings related to resistance?\",\"answer\":\"Resistance alterations were detected in 87% of samples when combining tissue and plasma genomics, with multiple resistance alterations in 46%. TP53 and MDM2/4 alterations were mutually exclusive and occurred in 86% of tumors, and PI3K pathway, SOX2, and MYC alterations were frequently observed in histologically transformed tumors.\"}]","Genomic Profiling of Epidermal Growth Factor Receptor Mutation–Positive Non–Small Cell Lung Cancer after Progression on First-line Osimertinib - Phase II ORCHARD Study | PDF",1790155646,28,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/61fd549754f41a6edf0f4348576fd71b.webp",983,1315,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4f8904a8187e36b257109f1779b19ade.webp",982,1314,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/77a51bff641477d317ea6062fd0a4cd5.webp",981,1312,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ee5ef147c0f66ec331a3eef73284e2db.webp",980,1311]